Dyne Therapeutics Reports Positive Phase 1/2 Trial Results

The latest update is out from Dyne Therapeutics ( (DYN) ).

On December 8, 2025, Dyne Therapeutics announced positive topline results from its Phase 1/2 DELIVER trial for zeleciment rostudirsen (z-rostudirsen) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The trial’s Registrational Expansion Cohort (REC) met its primary endpoint, showing a statistically significant increase in muscle content-adjusted dystrophin expression. Additionally, long-term data from the ongoing open-label and long-term extension portions of the trial demonstrated sustained functional improvement and a favorable safety profile. These results position Dyne Therapeutics to submit for U.S. Accelerated Approval in the second quarter of 2026, with a potential U.S. launch in the first quarter of 2027, assuming FDA approval.

The most recent analyst rating on (DYN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Spark’s Take on DYN Stock

According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.

Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.

To see Spark’s full report on DYN stock, click here.

More about Dyne Therapeutics

Dyne Therapeutics, Inc. is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

Average Trading Volume: 2,630,930

Technical Sentiment Signal: Buy

Current Market Cap: $2.9B

For an in-depth examination of DYN stock, go to TipRanks’ Overview page.